Internal medicine journal · 2026
Caring for Australians and New ZealandeRs with kidney Impairment guideline commentary on kidney disease: improving global outcomes 2025 guidelines for diagnosis and management of autosomal polycystic kidney disease.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abdy Mia E, St Pierre Kitty, Major Emily, Alexander Stephen I, Cashmore Brydee, Coolican Helen, Cullen Vanessa, Dawson Jessica, Lambert Kelly, Lee Vincent W, Mallawaarachi Amali, Rangan Gopala, Savige Judy, Varughese Santosh, Tunnicliffe David J, Mallett Andrew J, CARI Guidelines Steering Committee
Аннотация
Autosomal polycystic kidney disease (ADPKD) is the most common form of inherited kidney disease. The international guideline developer, Kidney Disease: Improving Global Outcomes (KDIGO), published a 2025 clinical practice guideline reflecting advances in genetic testing and the first disease-modifying agent, tolvaptan. However, KDIGO guidelines do not address healthcare access or equity issues relevant to the needs of our populations in Australia and New Zealand. The Caring for Australians and New ZealandeRs with kidney Impairment (CARI) Guidelines Working Group has provided a regional commentary to contextualise the KDIGO 2025 ADPKD guideline. This commentary aims to support clinicians in applying the KDIGO ADPKD 2025 guidance within our local health systems and highlights challenges in the implementation, including public subsidy limitations for recommended genetic testing and treatments. It also addresses equity concerns such as rural and remoteness, ensuring guidance is relevant to Australia and New Zealand.